The Rise of Plant-Based Vaccines Market and Its Impact on Transforming Strategies And Comprehensive Study

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Plant-Based Vaccines Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:

The plant-based vaccines market size has grown rapidly in recent years. It will grow from $1.52 billion in 2023 to $1.68 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to traditional vaccine production challenges, need for cost-effective vaccine production, emergence of plant molecular farming, reduced allergenic potential, synthetic biology applications.

The plant-based vaccines market size is expected to see rapid growth in the next few years. It will grow to $2.5 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to pandemic preparedness, global health security, expansion of vaccine applications, pharmaceutical industry adoption, . Major trends in the forecast period include technological advancements in plant biotechnology, environmental sustainability, integration of artificial intelligence, integration of ml.

Get Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12144&type=smp

Market Segmentation:
The plant-based vaccines market covered in this report is segmented -

1) By Vaccine Type: Bacterial Vaccines, Viral Vaccines, Parasite Vaccines, Other Vaccine Types
2) By Source: Tobacco Plant, Maize, Potato, Other Sources
3) By Application: Influenza, Zika Virus, Ebola Virus, Poultry Disease, Other Applications

Major Driver - Increased Prevalence Of Infectious Diseases Fuels Growth In The Plant-Based Vaccine Market

The high prevalence of infectious diseases is expected to propel the growth of the plant-based vaccine market going forward. Infectious diseases refer to ailments from germs like bacteria, viruses, fungi, or parasites. Plant-based vaccines, employed in traditional and modern medicine for various illnesses, including infectious diseases, can create secure, effective, stable, and reasonably priced prophylactics, vaccines, and medications. For instance, in October 2022, according to the Global Tuberculosis Report published by the World Health Organization, a Switzerland-based global health agency, the global incidence of tuberculosis (TB) was estimated at 10.6 million cases, with a rate of 134 cases per 100,000 population. TB cases were reported in the Southeast Asia region, accounting for 45% of the total, followed by Africa with 23% of the cases. Therefore, the high prevalence of infectious diseases is driving the growth of the plant-based vaccine market.

Competitive Landscape:

Major companies operating in the plant-based vaccines market report are Sanofi Pasteur SA, GlaxoSmithKline plc., British American Tobacco PLC, ICON Plc., Agenus Inc., Medicago Inc., Panacea Biotec Limited, Creative Biolabs Inc., InVitria, Fraunhofer USA Inc., Biodextris Inc., Intravacc B.V, Avesthagen Limited, Calyxt Inc., Zyus Life Sciences Inc., Mapp Biopharmaceutical Inc., Entos Pharmaceuticals Inc., Kentucky BioProcessing Inc., Planet Biotechnology Inc., Icon Genetics GmbH, PlantForm Corporation, LenioBio GmbH, Synbiotic Health Inc., Altimmune Inc., Oramed Pharmaceuticals Inc., iBio Inc., Lumen Bioscience Inc., Baiya Phytopharm Co. Ltd., Greenovation Biotech GmbH, Pevion Biotech AG

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/plant-based-vaccines-global-market-report

Top Trend - Key Players Pioneering Plant-Based Covid-19 Vaccine Innovation To Sustain Their Position In The Market

Product innovation is a key trend gaining popularity in the plant-based vaccine market. Major companies operating in the plant-based vaccine market are focused on developing innovative products to sustain their position in the market. For instance, in February 2022, Medicago Inc., a Canada-based biopharmaceutical company, and GSK PLC, a UK-based pharmaceutical and biotechnology company, announced that Health Canada had approved COVIFENZ, the COVID-19 vaccine. COVIFENZ, the COVID-19 vaccine, is the first plant-based virus-like particles [VLP], recombinant, adjuvanted vaccine available for coronavirus disease. COVIFENZ uses the coronavirus-like particle (CoVLP) technology. The vaccine comprises recombinant spike (S) glycoproteins produced as virus-like particles (VLPs).

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Plant-Based Vaccines Market Characteristics
3. Plant-Based Vaccines Market Trends And Strategies
4. Plant-Based Vaccines Market - Macro Economic Scenario
5. Plant-Based Vaccines Market Size And Growth
…..
27. Plant-Based Vaccines Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

This release was published on openPR.